FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>CARTER BRUCE L A</u>			<u>E</u> 1	2. Issuer Name and Ticker or Trading Symbol ENANTA PHARMACEUTICALS INC ENTA							(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last)		First) ARMACEUTICA	(Middle)		3. [	-	of Earliest	Trans	saction (Month/Day/Year)					Officer below)	(give title	Other below	(specify
500 ARSENAL STREET				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WATER	TOWN I	MA	02472												iled by More	Reporting Per than One Re	
(City)	(	State)	(Zip)		R			` '	Transa				to a contr	act instructio	n or written n	lan that is inten	ed to
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																	
			le I - Non						<del>-</del>		•			_			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr. 5)			ties Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amour Securities Beneficia Owned F	s Formally (D) of ollowing (I) (II)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	Amou	mount (A) or (D)		Price	Transact (Instr. 3 a	ion(s)		(Instr. 4)	
		-	Table II - D						uired, Dis , options					Owned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution D if any (Month/Day/	ate,	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		of Se Unde Deriv	7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership tt (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiratio Date	n Title		Amount or Number of Shares				
Stock Option (right to buy)	\$15.66	03/06/2024			A		15,700		(1)	03/06/203		nmon ock	15,700	\$0	15,700	D	

## Explanation of Responses:

1. Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders.

/s/ Paul J. Mellett as attorney-

in-fact

\*\* Signature of Reporting Person

Date

03/08/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.